In celebration of the authorization of Phase 2b/3 for JointStem

Dear customers, shareholders and staffs!

First of all, I wish you health and peace. Thanks to your support and encouragement, Phase 2b/3 of the clinical test for JointStem has been authorized.
After the clinical trial plan for Phase 2b/3 was approved by the Food and Drug administration last year, we prepared for the test under the right principles despite incessant threats from some of the creditors who lack the understanding on research and development and pursue only their personal interests. As a result, we finally launched a multi-organization clinical research team led by Professor Gang-il Kim, Director of the Joint Center of Gangdong Kyunghee University Hospital, and consisting of the best experts in regenerative arthritis in South Korea.

The plan has been revised and approved by the Clinical Ethics Committees of Gangdong Kyunghee University Hospital and Gangnam Severance Hospital. The revisions were reported as of June 9th.

We will begin to recruit subjects around June 20th.

We at Stem Cell Research Institute will do our best to successfully complete Phase 2b and begin Phase 3 of the test no later than the second half of 2016.I would like to express my gratitude for you, our companion to the journey to overcome incurable diseases. May the God’s blessing be with you, always.

2015. 6. 10.
Biostar Technology Research Center (Director:Jeong-chan Ra)